Thoroughbred Financial Services LLC Invests $217,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

Thoroughbred Financial Services LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILDFree Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 2,680 shares of the biopharmaceutical company’s stock, valued at approximately $217,000.

Several other hedge funds also recently modified their holdings of GILD. Norges Bank acquired a new stake in shares of Gilead Sciences during the fourth quarter worth approximately $1,301,624,000. Clearbridge Investments LLC increased its holdings in shares of Gilead Sciences by 179.0% in the third quarter. Clearbridge Investments LLC now owns 4,543,985 shares of the biopharmaceutical company’s stock valued at $340,526,000 after purchasing an additional 2,915,141 shares in the last quarter. abrdn plc increased its holdings in shares of Gilead Sciences by 89.0% in the fourth quarter. abrdn plc now owns 3,764,107 shares of the biopharmaceutical company’s stock valued at $304,930,000 after purchasing an additional 1,772,887 shares in the last quarter. International Assets Investment Management LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $133,584,000. Finally, AEGON ASSET MANAGEMENT UK Plc acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $63,971,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on GILD shares. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Friday, April 26th. UBS Group lowered their target price on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Cantor Fitzgerald lowered their target price on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a report on Wednesday, February 7th. Mizuho lowered their target price on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a report on Thursday, February 22nd. Finally, Morgan Stanley lowered their target price on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a report on Friday, April 26th. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Gilead Sciences presently has a consensus rating of “Hold” and a consensus price target of $83.69.

View Our Latest Stock Report on Gilead Sciences

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the sale, the insider now directly owns 96,304 shares in the company, valued at approximately $7,026,339.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Trading Up 0.8 %

GILD opened at $67.80 on Thursday. The stock has a market capitalization of $84.47 billion, a P/E ratio of 188.33, a P/E/G ratio of 1.35 and a beta of 0.22. Gilead Sciences, Inc. has a 12 month low of $64.33 and a 12 month high of $87.86. The firm’s fifty day simple moving average is $68.77 and its 200 day simple moving average is $74.70. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31.

Gilead Sciences (NASDAQ:GILDGet Free Report) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The firm had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. During the same period in the previous year, the business earned $1.37 EPS. The company’s revenue was up 5.3% compared to the same quarter last year. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 3.74 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be paid a $0.77 dividend. The ex-dividend date is Friday, June 14th. This represents a $3.08 annualized dividend and a yield of 4.54%. Gilead Sciences’s payout ratio is currently 855.56%.

About Gilead Sciences

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Read More

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDFree Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.